Business Context and Reporting Period
This Form 8-K is filed by Sunshine Heart, Inc. (not Nuwellis, Inc.) for the reporting period of August 31, 2015. The registrant is a Delaware corporation developing the C-Pulse Heart Assist System, a medical device designed to treat heart failure.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory milestone and does not contain financial statements or performance data.
Material Changes
The material event reported is the approval by the U.S. Food and Drug Administration (FDA) of a key protocol amendment for the Company's COUNTER HF pivotal study. This study is a prospective, randomized, multi-center, controlled trial evaluating the safety and efficacy of the C-Pulse system for NYHA Class III and ambulatory Class IV heart failure.
Outlook, Risks, and Management Commentary
Management highlights that the COUNTER HF study assesses the C-Pulse system's unique balloon counterpulsation treatment, which aims to improve heart function and reduce re-hospitalizations due to worsening heart failure. The filing does not explicitly list new risks, contingencies, or unusual items beyond the standard regulatory process context.
Investor Verification Checklist
- Verify the specific details of the FDA-approved protocol amendment in the attached press release (Exhibit 99.1).
- Confirm the current status and enrollment progress of the COUNTER HF pivotal study.
- Review the Company's most recent 10-K or 10-Q filings for actual financial performance data, as this 8-K contains none.
- Monitor future regulatory communications regarding the study's completion and potential FDA approval of the C-Pulse system.